Invivogen
Menu

REGN-CoV2-derived Anti-SARS-CoV-2 RBD mIgG2a antibodies

Anti-CoV2RBD-cas-mIgG2a Unit size Cat. code Docs Qty Price
Recombinant monoclonal mouse IgG2a (Casirivimab-derived)
100 µg
srbdc3-mab10
+-
$346.00
Anti-CoV2RBD-imd-mIgG2a Unit size Cat. code Docs Qty Price
Recombinant monoclonal mouse IgG2a (Imdevimab-derived)
100 µg
srbdc4-mab10
+-
$346.00

You may also need : Human ACE2 & TMPRSS2 expressing A549 Cells | View more associated products

Specific SARS-CoV-2 Spike-RBD recombinant mouse IgG2a antibodies

SARS-CoV-2 specific neutralization by Casirivimab & Imdevimab
SARS-CoV-2 specific neutralization by Casirivimab & Imdevimab

Antibody description

InvivoGen provides a set of recombinant monoclonal antibodies (mAbs) featuring a mouse IgG2a constant region, and the variable region of 'Casirivimab (REGN10933)' or 'Imdevimab (REGN10987'),  two clones originally described as potent  SARS-CoV-2 neutralizing mAbs [1]:

— Anti-CoV2RBD-cas-mIgG2a (derived from Casirivimab)

— Anti-CoV2RBD-imd-mIgG2a (derived from Imdevimab)
 

InvivoGen's Anti-CoV2RBD-cas-mIgG2a and Anti-CoV2RBD-imd-mIgG2a have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography, ensuring lot-to-lot reproducibility. Furthermore, these mAbs have been functionally validated by ELISA (see data below). The absence of bacterial contamination has been confirmed by cellular assays. 

Background

Casirivimab and Imdevimab were generated using both humanized mice and convalescent patients [1]. These mAbs specifically target two distinct and non-overlapping regions of the SARS-CoV-2 S-RBD and potently block its binding to the ACE2 receptor on target cells [1]. 

 More details

Applications

  • Detecting the presence of SARS-CoV-2 in culture supernatant and/or in serum (ELISA)
  • Flow cytometry binding assays 
  • Developing neutralizing antibody cocktails against SARS-CoV-2
  • Monitoring SARS-CoV-2 variant escape

Quality control

  • Functionally validated by ELISA using coated Spike-RBD proteins derived from SARS-CoV-2 variants

 

References

1. Hansen J. et al., 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369:1010-1014.

Figures

ELISA with Anti-CoV2RBD-(cas or imd)-mIgG2a mAbs
ELISA with Anti-CoV2RBD-(cas or imd)-mIgG2a mAbs

SARS-CoV-2 Spike-RBD proteins (3 μg/ml) derived from the Wuhan (A), United Kingdom (U.K.) (B), or South-Africa (S.A.) (C) variants were coated on ELISA plates overnight. A 3-fold serial dilution of Anti-CoV2RBD-imd-IgG2a (red curve), Anti-CoV2RBD-cas-mIgG2a (orange curve), CR3022-derived Anti-Spike-RBD mIgG2a (back curve), of Anti-βGal-mIgG2a antibodies (grey curve) was performed for the capture step. A HRP-labelled Anti-mIgG2a antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

Back to the top

Specifications

Specificity: SARS-CoV-2 Spike RBD
Clonality: Monoclonal
Isotype: mIgG2a
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
Purification: purified by affinity chromatography with protein A
Quality control:

  • The complete sequence of each antibody construct has been verified.
  • Antibody binding has been validated by ELISA using coated Spike-RBD proteins derived from SARS-CoV-2 variants.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Back to the top

Contents

Note: Each antibody is sold separately.

 
  • 100 µg purified antibody, azide-free, and lyophilized

room temperature The product is shipped at room temperature.

store Store lyophilized antibody at -20 °C.

stability Lyophilized product is stable for at least 1 year.

Back to the top

Details

Casirivimab and Imdevimab were generated using both humanized mice and convalescent patients [1]. These mAbs specifically target two distinct and non-overlapping regions of the SARS-CoV-2 S-RBD and potently block its binding to the ACE2 receptor on target cells [1]. Treatment using a combination of these mAbs (known as REGEN-COV™ or REGN-COV2) has been authorized under emergency use for COVID-19 outpatients [2-4]. Prophylactic and therapeutic administration of this mAb cocktail almost completely blocks the establishment of virus infection in non-human primates [5] and enhances clearance of the virus in patients whose endogenous immune response has not yet been initiated [2].

 

Learn more about the SARS-CoV-2 Spike protein.

 

References

1. Hansen J. et al., 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369:1010-1014.
2. Weinreich D.M. et al., 2021. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 384(3):238-251.
3. https://www.fda.gov/media/145610/download.
4. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimab. 

5. Baum A. et al., 2020. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370:1110-1115.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty